SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marina Berenguer, John R. Lake, Transplantation of the Liver, 2015,

    CrossRef

  2. 2
    Jennifer E. Layden, Bamidele O. Tayo, Scott J. Cotler, Nina M. Clark, Kristine Baraoidan, Scott L. Friedman, Richard S. Cooper, Association of Genetic Variants With Rapid Fibrosis, Transplantation, 2014, 97, 10, 1072

    CrossRef

  3. 3
    Ling Zhang, Qian Lu, Zhiqing Yang, Xiaojun Wang, Lei Cai, Xiangde Liu, Rui Liao, Xing Yang, Yinzhi Chen, Zhanyu Yang, Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis, Human Immunology, 2014, 75, 12, 1268

    CrossRef

  4. 4
    Norah A. Terrault, R. Todd Stravitz, Anna S.F. Lok, Greg T. Everson, Robert S. Brown, Laura M. Kulik, Kim M. Olthoff, Sammy Saab, Ovedele Adeyi, Curtis K. Argo, Jay E. Everhart, Del R. Rodrigo, Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study, Hepatology, 2014, 59, 4
  5. 5
    J. Howell, P. Angus, P. Gow, Hepatitis C recurrence: the Achilles heel of liver transplantation, Transplant Infectious Disease, 2014, 16, 1
  6. 6
    Tzu-Hao Lee, Hans L. Tillmann, Keyur Patel, Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy, Molecular Diagnosis & Therapy, 2014, 18, 1, 25

    CrossRef

  7. 7
    Mostafa K. El Awady, Noha G. Bader El Din, Mahmoud Abdel Aziz Riad, Moataza H. Omran, Tawfeek H. Abdelhafez, Tamer Mahmoud Elbaz, Shereen Shoukry Hunter, Reham M. Dawood, Ashraf O. Abdel Aziz, Predictors of Disease Recurrence Post Living Donor Liver Transplantation in End Stage Chronic HCV Patients, Disease Markers, 2014, 2014, 1

    CrossRef

  8. 8
    Deepak Joshi, Massimo Pinzani, Ivana Carey, Kosh Agarwal, Recurrent HCV after liver transplantation—mechanisms, assessment and therapy, Nature Reviews Gastroenterology and Hepatology, 2014, 11, 12, 710

    CrossRef

  9. 9
    P. Manousou, E. Cholongitas, D. Samonakis, E. Tsochatzis, A. Corbani, A. P. Dhillon, J. Davidson, M. Rodriguez-Peralvarez, D. Patch, J. O'Beirne, D. Thorburn, T. Luong, K. Rolles, B. Davidson, P. A. McCormick, P. Hayes, A. K. Burroughs, Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes, Gut, 2014, 63, 6, 1005

    CrossRef

  10. 10
    Marina Kawaguchi-Suzuki, Reginald F. Frye, The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014, 34, 2
  11. 11
    A.J. Thompson, P. Clark, A. Aghemo, Handbook of Pharmacogenomics and Stratified Medicine, 2014,

    CrossRef

  12. 12
    Roberto J. Firpi, Huijia Dong, Virginia C. Clark, Consuelo Soldevila-Pico, Giuseppe Morelli, Roniel Cabrera, Oxana Norkina, Jonathan J. Shuster, David R. Nelson, Chen Liu, CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant, Liver International, 2013, 33, 1
  13. 13
    Gonzalo Crespo, José A. Carrión, Mairene Coto-Llerena, Zoe Mariño, Sabela Lens, Sofía Pérez-del-Pulgar, Montserrat García-Retortillo, Rosa Miquel, Jaime Bosch, Miquel Navasa, Xavier Forns, Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation, Journal of Gastroenterology, 2013, 48, 6, 762

    CrossRef

  14. 14
    Dennis Eurich, Sabine Boas-Knoop, Benjamin Struecker, Ruth Neuhaus, Peter Neuhaus, Marcus Bahra, Genetic Variants of STAT-4 Affect the Development of Graft Fibrosis After Liver Transplantation for HCV-Induced Liver Disease, Transplantation Journal, 2013, 95, 1, 203

    CrossRef

  15. 15
    Giacomo Germani, Emmanuel Tsochatzis, Vasilios Papastergiou, Andrew K Burroughs, HCV in liver transplantation, Seminars in Immunopathology, 2013, 35, 1, 101

    CrossRef

  16. 16
    Susanne Beckebaum, Iyad Kabar, Vito R. Cicinnati, Hepatitis B and C in liver transplantation: new strategies to combat the enemies, Reviews in Medical Virology, 2013, 23, 3
  17. 17
    David G. Bowen, Nicholas A. Shackel, Hepatitis C pathogenesis and outcomes after liver transplantation: Probing microRNA expression for new insights, Liver Transplantation, 2013, 19, 4
  18. 18
    Markus H. Heim, Innate immunity and HCV, Journal of Hepatology, 2013, 58, 3, 564

    CrossRef

  19. 19
    Andres Duarte-Rojo, Matthew G. Deneke, Michael R. Charlton, Interleukin-28B polymorphism in hepatitis C and liver transplantation, Liver Transplantation, 2013, 19, 1
  20. 20
    Nobuhisa Akamatsu, Yasuhiko Sugawara, Living-Donor Liver Transplantation and Hepatitis C, HPB Surgery, 2013, 2013, 1

    CrossRef

  21. 21
    Geeta S. Karnik, Kirti Shetty, Management of Recurrent Hepatitis C in Orthotopic Liver Transplant Recipients, Infectious Disease Clinics of North America, 2013, 27, 2, 285

    CrossRef

  22. You have free access to this content22
    D. Joshi, I. Carey, K. Agarwal, Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients, Alimentary Pharmacology & Therapeutics, 2013, 37, 7
  23. 23
    Christian M. Lange, The importance of IL28B genotype in hepatitis C virus-associated liver transplantation, Liver International, 2013, 33, 2
  24. 24
    Kosh Agarwal, Ashley Barnabas, Treatment of chronic hepatitis C virus infection after liver transplantation, Digestive and Liver Disease, 2013, 45, S349

    CrossRef

  25. 25
    Dennis Eurich, Ulf P Neumann, Sabine Boas-Knoop, Ruth Neuhaus, Anja Kiessling, Ali Yahyazadeh, Christian Trautwein, Hermann Wasmuth, Gero Puhl, Peter Neuhaus, Marcus Bahra, YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  26. 26
    Nicole T. do O, Dennis Eurich, Petra Schmitz, Maximilian Schmeding, Christoph Heidenhain, Marcus Bahra, Christian Trautwein, Peter Neuhaus, Ulf P. Neumann, Hermann E. Wasmuth, A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection, Liver Transplantation, 2012, 18, 3
  27. 27
    J. A. Holmes, P. V. Desmond, A. J. Thompson, Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?, Journal of Viral Hepatitis, 2012, 19, 10
  28. 28
    Ivo W. Graziadei, Heinz M. Zoller, Anna Schloegl, Karin Nachbaur, Karl-Peter Pfeiffer, Walter Mark, Gregor Mikuz, Johann Pratschke, Raimund Margreiter, Wolfgang Vogel, Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation, Liver Transplantation, 2012, 18, 6
  29. 29
    Julieta Trinks, Adrián Gadano, Pablo Argibay, Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome, Epidemiology Research International, 2012, 2012, 1

    CrossRef

  30. 30
    Varun Saxena, Norah Terrault, Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies, Current Opinion in Organ Transplantation, 2012, 17, 3, 216

    CrossRef

  31. 31
    Paul J Clark, Alexander J Thompson, Host genomics and HCV treatment response, Journal of Gastroenterology and Hepatology, 2012, 27, 2
  32. 32
    Alison Jazwinski, Andrew Muir, IL28B: Implications for Clinical Practice, Current Hepatitis Reports, 2012, 11, 1, 15

    CrossRef

  33. 33
    Elisa Cisneros, Isolina Baños, María Jesús Citores, Ana Duca, Clara Salas, Ana Noblejas, María Cañizares, Isabel Millán, Valentín Cuervas-Mons, Carlos Vilches, Increased Risk of Severe Hepatitis C Virus Recurrence After Liver Transplantation in Patients With a T Allele of IL28B rs12979860, Transplantation Journal, 2012, 94, 3, 275

    CrossRef

  34. 34
    Tomokazu Kawaoka, Shoichi Takahashi, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Nobuhiko Hiraga, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Takashi Onoe, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama, Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  35. 35
    Nicholas A. Shackel, Looking into Pandora's box , Liver Transplantation, 2012, 18, 3
  36. 36
    Y. Chen, H.-X. Xu, L.-J. Wang, X.-X. Liu, R. I. Mahato, Y.-R. Zhao, Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin, Alimentary Pharmacology & Therapeutics, 2012, 36, 2
  37. 37
    Alleluiah Rutebemberwa, Hugo R. Rosen, Of mice and men, calcineurin inhibitors and hepatitis C, Liver Transplantation, 2012, 18, 1
  38. 38
    Maria Francesca Donato, Enrico Galmozzi, Cristina Rigamonti, Alessio Aghemo, Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients, Journal of Hepatology, 2012, 56, 6, 1422

    CrossRef

  39. 39
    Varun Saxena, Jennifer C. Lai, Jacqueline G. O'Leary, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, James F. Trotter, Kartik Krishnan, Norah A. Terrault, Recipient-Donor race mismatch for African American liver transplant patients with chronic hepatitis C, Liver Transplantation, 2012, 18, 5
  40. 40
    Dennis Eurich, Sabine Boas-Knoop, Marcus Bahra, Ruth Neuhaus, Rajan Somasundaram, Peter Neuhaus, Ulf Neumann, Daniel Seehofer, Role of IL28B Polymorphism in the Development of Hepatitis C Virus-Induced Hepatocellular Carcinoma, Graft Fibrosis, and Posttransplant Antiviral Therapy, Transplantation, 2012, 1

    CrossRef

  41. 41
    D. Eurich, S. Boas-Knoop, A. Yahyazadeh, R. Neuhaus, R. Somasundaram, M. Ruehl, G. Puhl, P. Neuhaus, U.P. Neumann, M. Bahra, Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease, Transplant Infectious Disease, 2012, 14, 5
  42. 42
    Andres Duarte-Rojo, Bart J. Veldt, David D. Goldstein, Hans L. Tillman, Kymberly D. Watt, Julie K. Heimbach, John G. McHutchison, John J. Poterucha, Florencia Vargas-Vorackova, Michael R. Charlton, The Course of Posttransplant Hepatitis C Infection, Transplantation Journal, 2012, 94, 2, 197

    CrossRef

  43. 43
    Nicholas A Shackel, When has the horse bolted?, Journal of Gastroenterology and Hepatology, 2012, 27, 7
  44. 44
    Eleonora De Martin, Kryssia I Rodriguez-Castro, Alessandro Vitale, Giacomo Zanus, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra, Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?, Future Virology, 2011, 6, 10, 1179

    CrossRef

  45. 45
    Dennis Eurich, Sabine Boas-Knoop, Lars Morawietz, Ruth Neuhaus, Rajan Somasundaram, Martin Ruehl, Ulf P. Neumann, Peter Neuhaus, Marcus Bahra, Daniel Seehofer, Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma, Liver International, 2011, 31, 7
  46. 46
    Ulf Neumann, Impact ofIL-28Bpolymorphism on outcome in patients with hepatitis C after liver transplantation, Expert Review of Gastroenterology & Hepatology, 2011, 5, 4, 429

    CrossRef

  47. 47
    Geoffrey W. McCaughan, Nicholas A. Shackel, David G. Bowen, Liver transplantation and hepatitis C: Will understanding the interleukin-28B polymorphisms improve outcomes?, Liver Transplantation, 2011, 17, 3
  48. 48
    Ed Gane, Liver Transplantation for Chronic Hepatitis B and C,